| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8815780 | Journal of Affective Disorders | 2018 | 36 Pages |
Abstract
Overall, the available evidence does not indicate greater benefits or fewer harms of levomilnacipran, vilazodone, and vortioxetine compared with other second-generation antidepressants.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
Gernot Wagner, Marie-Therese Schultes, Viktoria Titscher, Birgit Teufer, Irma Klerings, Gerald Gartlehner,